Journal of Humanistic Psychology
June 23, 2021
Julie B. Wang, Jessica Lin, Leah Bedrosian et al.
22 citations
Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and functional impairment. Previous MDMA–assisted therapy (MDMA-AT) studies have shown promising results in single site studies. Two open-label studies tested this modality in multisite clinical trials to assess the feasibility of scaling this manualized...
Mental Health Weekly
May 17, 2021
Valerie A. Canady
1 citation
New research involving the use of psychedelic‐assisted therapy is showing promise and significant implications for patients with severe, chronic post‐traumatic stress disorder (PTSD) and could potentially move the needle further toward Food and Drug Administration (FDA) approval, say researchers from the Multidisciplinary Association for Psychedelic Studies (MAPS).
Journal of Psychopharmacology
April 22, 2021
Robin Carhart-Harris, Anne C Wagner, Manish Agrawal et al.
54 citations
Favourable regulatory assessments, liberal policy changes, new research centres and substantial commercial investment signal that psychedelic therapy is making a major comeback. Positive findings from modern trials are catalysing developments, but it is questionable whether current confirmatory trials are sufficient for advancing our understanding of safety and best practice. Here we suggest...
Harm Reduction Journal
April 11, 2021
Brian Pilecki, Jason B. Luoma, Geoff J. Bathje et al.
135 citations
Abstract Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own...
medRxiv Preprint Server
April 10, 2021
Agnes Norbury, Sarah B. Rutter, Abigail B. Collins et al.
1 citation
preprint
Promising initial data indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may be beneficial in post-traumatic stress disorder (PTSD). Here, we explore the neural correlates of ketamine-related changes in PTSD symptoms, using a rich battery of functional imaging data (two emotion-processing tasks and one task-free scan), collected from a subset of participants...
2021
Felix Betzler, Gerhard Gründer, Matthew W. Johnson et al.
Purpose of Review: The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. However, as psychedelic substances are still commonly known for their ( illicit) recreational use, it may seem counterintuitive to use psychedelic therapy to treat substance use disorders. This review aims to discuss how psychedelics can promote and...
ACS Pharmacology & Translational Science
December 10, 2020
David B. Yaden, Roland R. Griffiths
534 citations
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not...
Frontiers in Psychiatry
November 26, 2020
Bénédicte Nobile, Emilie Olié, Philippe Courtet
2 citations
In their recent article entitled “Psychedelic Psychiatry's Brave New World,” Nutt et al. (1) wrote that new research on psychedelic drugs, especially psilocybin, has highlighted their potential for psychiatric disorder management. In the past decade, many studies focused on psilocybin effects on mood disorders (2) showing that it can significantly improve depressive symptomatology for weeks and...
CNS Drugs
August 17, 2020
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet et al.
217 citations
This review demonstrates how qualitative research of psychedelic treatments can contribute to distinguishing specific features of specific substances, and carry otherwise undiscovered implications for the treatment of specific psychiatric disorders.
Therapeutic Advances in Psychopharmacology
August 14, 2020
Jacob S. Aday, Christopher C. Davoli, Emily K. Bloesch
50 citations
Psychedelic drugs and virtual reality (VR) each have the capacity to disrupt the rigidity and limitations of typical conscious experience. This article delineates the parallels among psychedelic and VR states as well as their potential synergistic applications in clinical and recreational settings. Findings indicate that, individually, psychedelics and VR are used in analogous ways to alter...